A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2017
At a glance
- Drugs CMB 305 (Primary) ; Atezolizumab
- Indications Liposarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- Sponsors Immune Design
- 02 Aug 2017 According to an Immune Design media release, early data from the study will be presented at the European Society for Medical Oncology 2017 Congress (ESMO).
- 10 Jun 2017 Biomarkers information updated
- 17 May 2017 According to an Immune Design media release, the company intends to submit early data from a pre-specified analysis of this study for presentation at the European Society for Medical Oncology 2017 Congress.